Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients

According to preliminary data, seroconversion after mRNA SARS-CoV-2 vaccination might be unsatisfactory in Kidney Transplant Recipients (KTRs). However, it is unknown if seronegative patients develop at least a cellular response that could offer a certain grade of protection against SARS-CoV-2. To a...

Descripción completa

Detalles Bibliográficos
Autores: Cucchiari, David|||0000-0002-7594-1070, Egri, Natalia|||0000-0001-7698-0672, Bodro, Marta|||0000-0002-0520-8279, Herrera, Sabina|||0000-0002-5057-354X, Del Risco-Zevallos, Jimena, Casals-Urquiza, Joaquim, Cofan, Frederic|||0000-0003-4163-9620, Moreno Camacho, Asunción|||0000-0001-6382-0039, Rovira, Jordi|||0000-0001-8737-5005, Banon-Maneus, Elisenda, Ramirez-Bajo, Maria J.., Ventura-Aguiar, Pedro|||0000-0003-3381-7503, Pérez-Olmos, Anna, Garcia-Pascual, Marta, Pascal, Mariona|||0000-0003-0549-9720, Vilella, Anna|||0000-0002-2329-676X, Trilla, Antoni, Ríos, José|||0000-0002-0716-8784, Palou, Eduard|||0000-0003-1544-1485, Juan, Manel|||0000-0002-3064-1648, Bayés Genís, Beatriu|||0000-0003-1233-7631, Diekmann, Fritz|||0000-0001-6199-3016
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:245165
Acceso en línea:https://ddd.uab.cat/record/245165
https://dx.doi.org/urn:doi:10.1111/ajt.16701
Access Level:acceso abierto
Palabra clave:Clinical research/practice
Infection and infectious agents-viral
Infectious disease
Kidney transplantation/nephrology
Vaccine
Descripción
Sumario:According to preliminary data, seroconversion after mRNA SARS-CoV-2 vaccination might be unsatisfactory in Kidney Transplant Recipients (KTRs). However, it is unknown if seronegative patients develop at least a cellular response that could offer a certain grade of protection against SARS-CoV-2. To answer this question, we prospectively studied 148 recipients of either kidney (133) or kidney-pancreas (15) grafts with assessment of IgM/IgG spike (S) antibodies and ELISpot against the nucleocapside (N) and the S protein at baseline and two weeks after receiving the second dose of the mRNA-1273 (Moderna) vaccine. At baseline, 31 patients (20.9%) had either IgM/IgG or ELISpot positivity and were considered to be SARS-CoV-2-pre-immunized, while 117 (79.1%) patients had no signs of either cellular or humoral response and were considered SARS-CoV-2-naïve. After vaccination, naïve patients who developed either humoral or cellular response were finally 65.0%, of which 29.9% developed either IgG or IgM and 35.0% S-ELISpot positivity. Factors associated with vaccine unresponsiveness were diabetes and treatment with anti-thymocytes globulins during the last year. Side effects were consistent with that of the pivotal trial and no DSAs developed after vaccination. In conclusion, mRNA-1273 SARS-CoV-2 vaccine elicits either cellular or humoral response in almost two thirds of KTRs.

Similares en LA Referencia